



Europass Curriculum Vitae

Personal information

Surname(s) / First name(s) **Stacchiotti, Silvia**

Address(es) Fondazione IRCCS Istituto Nazionale dei Tumori
Oncologia Medica 2, Tumori Mesenchimali dell'Adulto e Tumori Rari
Via Giacomo Venezian, 1
20133 Milano – Italy

Telephone(s) +39 02 2390 2182

Fax(es) +39 02 2390 2804

E-mail silvia.stacchiotti@istitutotumori.mi.it

Nationality Italian

Date of birth 12 July 1968

Gender Female

Work experience

Dates From January 2013

Occupation or position held Full Staff Attending Physician

Main activities and responsibilities Full staff position as Medical Oncologist

Name and address of employer **Fondaz. IRCCS “Istituto Nazionale dei Tumori”**, via G. Venezian 1, 20133 **Milano**, Italy

Type of business Medical oncology involved in adult patients with sarcoma and other rare solid tumor care

Dates From August 2006 to December 2012

Occupation or position held Associate Physician

Main activities and responsibilities Non permanent full staff position as Medical Oncologist

Name and address of employer **Fondaz. IRCCS “Istituto Nazionale dei Tumori”**, via G. Venezian 1, 20133 **Milano**, Italy

Type of business Medical oncology involved in adult patients with sarcoma and other rare solid tumor care

Dates From January 2002 to July 2006

Occupation or position held Clinical Fellow Associate Physician

Main activities and responsibilities Non full staff position as Medical Oncologist

Name and address of employer **Fondaz. IRCCS “Istituto Nazionale dei Tumori”**, via G. Venezian 1, 20133 **Milano**, Italy

Type of business Medical oncology involved in adult patients with sarcoma and other rare solid tumor care

Dates From December 1999 to July 2000

Occupation or position held Associate physician

Main activities and responsibilities Non full staff position as physician

Name and address of employer **Fondaz. IRCCS “Istituto Nazionale dei Tumori”**, via G. Venezian 1, 20133 **Milano**, Italy

Type of business or sector Health care: internal medicine (Nutrition Unit)

Dates From April 1997 to March 1999
Occupation or position held Clinical Fellow
Main activities and responsibilities Non full staff position as physician
Name and address of employer H Fatebenefratelli Oftalmico, c.so p.ta Nuova, Milano, Italy
Type of business or sector Health care: internal medicine, emergency medicine, public health

Dates From July 1994 to June 1996
Occupation or position held Full staff Associate Physician
Main activities and responsibilities Full staff positions as physician
Name and address of employer Lacor Hospital, Gulu, Uganda (EAU)
Type of business or sector Health care: internal medicine, paediatrics

Education and training

Dates From 2002 to 2006
Title of qualification awarded **Board certificate in Clinical Oncology**
Principal subjects/occupational skills covered Clinical Oncology
Name and type of organisation providing education and training University, Milano, Italy
Level in national or international Classification ISCED 5A (Field of Education :72)

Dates From 1997 to 1999
Title of qualification awarded **Board certificate in General Medicine**
Principal subjects/occupational skills covered General Medicine
Name and type of organisation providing education and training University, Milano, Italy
Level in national or international classification ISCED 5A (Field of Education: 72)

Dates 1993
Title of qualification awarded **Italian Medical Licence**
Principal subjects/occupational skills covered Medicine
Name and type of organisation providing education and training University, Milano, Italy

Dates From 1987 to 1993
Title of qualification awarded **Medical Degree (cum laude)**
Principal subjects/occupational skills covered Medicine
Name and type of organisation providing education and training University, Milano, Italy
Level in national or international classification ISCED 5A (Field of Education: 72)

Personal skills and competences

Mother tongue(s) Italian

Other language(s) English

Self-assessment

European level (*)

English

Understanding				Speaking				Writing	
Listening		Reading		Spoken interaction		Spoken production			
C1	Proficient user	C1	Proficient user	C1	Proficient user	C1	Proficient user	C1	Proficient user

(*) *Common European Framework of Reference for Languages*

Additional information

- National Scientific Abilitation for associate professor of Medical Oncology (settore concorsuale 06/D3) until October 31st 2027
- President of the Italian sarcoma Group, starting from June 2021
- Member of the Associazione Italiana Oncologia medica (AIOM)
- Member of the European Society of Medical Oncology (ESMO)
- Faculty coordinator of the Sarcoma group of the European Society for Medical Oncology (ESMO) for the term of office 2021-2022.
- Member of the ESMO Guidelines Steering Committee, for the term 2022-2023
- Subject editor of the ESMO guidelines committee for sarcoma and GIST for the term of office 2019-2023
- Member of the ESMO OncologyPRO committee since 2019
- Member of the scientific committee of the Sarcoma Track for the ESMO annual meeting in 2016, 2017, 2018, 2019, 2022; member of the scientific committee of the Sarcoma Track for the ESMO-Asia annual meeting in 2019, 2020
- Member of the Board of Directors of the Connective Tissue Oncology Society (CTOS) for the term of office 2019-2021 and program Chair of the CTOS Annual Meeting 2020
- Member of the Board of Directors of Alleanza Contro il Cancro (ACC)
- Member of the Board of Directors of Federation of Italian Cooperative Oncology Groups (FICOG), starting from June 2021
- Member of the European Organization for Research and Treatment in Cancer (EORTC) Soft Tissue and Bone Sarcoma Group
- Chair of the Systemic Committee of the EORTC Soft Tissue and Bone Sarcoma Group
- Member of the American Society of Clinical Oncology (ASCO)
- Member of the European Medical Agency (EMA) list of external experts since 2015.
- Faculty member of College of European School of Oncology (ESCO) since 2020
- Member of the Chordoma Foundation advisory board since 2014
- Member of the Epithelioid Hemangioendothelioma Foundation advisory board since 2015
- Member of the Desmoid Tumor Research Foundation advisory board since 2016
- Member of the Scientific Review Board of Fondazione IRCCS Istituto Nazionale dei Tumori – Milan – Italy
- Member of the Life Raft Group TGCT Medical Advisory Board

- Associate editor of European Journal of Cancer since 2017
- Associate editor of Cancer since 2017

- GCP training: 09/2021
- Basic Life Support (CPR Adult, Child, Infant, Choking; AED; First-AID; Bloodborne Pathogens) training: May 2017
- Advanced Life Support: April 2018

- Principal investigaro of several national and international phase 1,2,3 clinical trials in adult soft tissue and bone sarcoma

Publications: see Annexes 1

Annexes Annex 1: List of Medline-indexed scientific publications, in English

Annex 1

List of Medline-indexed scientific publications, in English (H Index 52):

1. Gronchi A, Miah AB, Dei Tos AP, Abecassis N, Bajpai J., Bauer S, Biagini R, S. Bielack, J.Y. Blay, S. Bolle, S. Bonvalot, I. Boukovinas, J. V. M. G. Bovee, K. Boye B. Brennan, T. Brodowicz, A. Buonadonna, E. De Álava, X. G. Del Muro, A. Dufresne, M. Eriksson, F. Fagioli, A. Fedenko, V. Ferraresi, A. Ferrari, A. M. Frezza, S. Gasperoni, H. Gelderblom, F. Gouin, G. Grignani, R. Haas, A. B. Hassan, S. Hecker-Nolting, N. Hindi, P. Hohenberger, H. Joensuu, R. L. Jones, C. Jungels, P. Jutte, L. Kager, B. Kasper, A. Kawai, K. Kopeckova, D. A. Krákorová, A. Le Cesne, F. Le Grange, E. Legius, A. Leithner, A. Lopez-Pousa, J. Martin-Broto, O. Merimsky, C. Messiou, O. Mir, M. Montemurro, B. Morland, C. Morosi^{54E}, Palmerini, A. Pantaleo, R. Piana, S. Piperno-Neumann, P. Reichardt, P. Rutkowski, Safwat AA, Sangalli C, Sbaraglia M, S. Scheipl, Schöffski P, Sleijfer S, Strauss D, Strauss S, K. Sundby Hall, A. Trama, M. Unk, M. van de Sande AJ, van der Graaf WTA, van Houdt WJ, Frebourg T, Casali PG, **Stacchiotti S** on behalf of the ESMO Guidelines Committee, EURACAN and GENTURIS. **Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.** Annals Oncol 2021; 32:1348-1365.
2. **SELNET Clinical practice guidelines for soft tissue sarcoma and GIST.** Cancer Treatment Reviews 2021, in press.
3. Casali PG, Blay JY, Abecassis N, Bajpai J., Bauer S, Biagini R, S. Bielack, J.Y. Blay, S. Bolle, S. Bonvalot, I. Boukovinas, J. V. M. G. Bovee, K. Boye B. Brennan, T. Brodowicz, A. Buonadonna, E. De Álava, Dei Tos AP, X. G. Del Muro, A. Dufresne, M. Eriksson, F. Fagioli, A. Fedenko, V. Ferraresi, A. Ferrari, A. M. Frezza, S. Gasperoni, H. Gelderblom, F. Gouin, G. Grignani, R. Haas, A. B. Hassan, S. Hecker-Nolting, N. Hindi, P. Hohenberger, H. Joensuu, R. L. Jones, C. Jungels, P. Jutte, L. Kager, B. Kasper, A. Kawai, K. Kopeckova, D. A. Krákorová, A. Le Cesne, F. Le Grange, E. Legius, A. Leithner, A. Lopez-Pousa, J. Martin-Broto, O. Merimsky, C. Messiou, O. Mir, M. Montemurro, B. Morland, C. Morosi^{54E}, Palmerini, A. Pantaleo, R. Piana, S. Piperno-Neumann, P. Reichardt, P. Rutkowski, Safwat AA, Sangalli C, Sbaraglia M, S. Scheipl, Schöffski P, Sleijfer S, Strauss D, Strauss S, K. Sundby Hall, A. Trama, M. Unk, M. van de Sande AJ, van der Graaf WTA, van Houdt WJ, Frebourg T, Gronchi A, **Stacchiotti S** on behalf of the ESMO Guidelines Committee, EURACAN and GENTURIS. **Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.** Annals Oncol 2021, in press.
4. Yin O, Zahir H, French J, Polhamus D, Wang X, van de Sande M, Tap W, Gelderblom H, Wagner A, Healey J, Greenberg J, Shuster D, **Stacchiotti S.** **Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor.** Pharmacometrics and Systems Pharmacology 2021, in press.
5. Strauss SJ, Frezza AM, Abecassis N, Bajpai, J, Bauer S, Biagini R, Bielack B, Blay JY, Bolle S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brennan B, Brodowicz T, Buonadonna A, de Álava E, Dei Tos AP, Garcia del Muro X, Dufresne A, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Gaspar N, Gasperoni S, Gelderblom H, Gouin F, Grignani G, Gronchi A, Haas R, Hassan AB, Hecker-Nolting S, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kager L, Kasper B, Kawai A, Kopeckova K, Krákorová DA, Le Cesne A, Le Grange F, Legius E, Leithner A, López Pousa A, Martin-Broto J, Merimsky O, Messiou C, Miah AB, Mir O, Montemurro M, Morland B, Morosi C, Palmerini E, Pantaleo MA, Piana R, Piperno-Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Schöffski P, Sleijfer S, Strauss D, Sundby Hall K, Trama A, Unk M, van de Sande MAJ, van der Graaf WTA, van Houdt WJ, Frebourg T, Ladenstein R, Casali PG, **Stacchiotti S**, on behalf of the ESMO Guidelines Committee, EURACAN, GENTURIS and ERNPaedCan. **Bone sarcomas: ESMO-EURACAN-GENTURIS-ERNPaedCan: Clinical Practice Guidelines for diagnosis, treatment and follow-up.** Annals Oncol 2021, in press.
6. Martin-Broto J, Lopez-Alvarez M, Moura DS, Ramos R, Collini P, Romagosa C, Bagué S, Renne SL, Barisella M, Velasco V, Coindre JM, Lopez D, Dopazo J, Gambarotti M, Braglia M, Merlo D, Palmerini E, **Stacchiotti S**, Quagliuolo VL, Lopez-Pousa A, Grignani G, Blay JY, Brunello A, Gutierrez A, Valverde C, Hindi N, Dei Tos AP, Picci P, Casali PG, Gronchi A. **Predictive value of MRP-1 in localized high-risk soft tissue sarcomas: a translational research associated to ISG-STs 1001 randomized phase III trial.** Mol Cancer Ther 2021, in press.
7. Schöffski P, Kubickova M, Wozniak A, Blay JY, Strauss SJ, **Stacchiotti S**, Switaj S, Buecklein V, Leahy MG, Italiano A, Isambert N, Debiec-Rychter M, Sciot R, Lee CJ, Speetjens F, Nzokirantevye A, Neven A, Kasper B. **Long term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumor from EORTC trial 90101 CREATE.** Eur J Cancer 2021;156:12-23.
8. **Stacchiotti S**, Frezza AM, Blay JY, et al. **Ultra-rare sarcomas: a consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities.** Cancer 2021; 127:2934-2942.
9. Kantidakis G, Litière S, Neven A, Vinches M, Judson I, Schöffski P, Wardelmann E, **Stacchiotti S**, D'Ambrosio L, Marréaud S, van der Graaf WTA, Kasper B, Fiocco M, Gelderblom H. **Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for soft-tissue sarcomas.** Eur J Cancer 2021, 154:253-268.
10. Pasquali S, Palmerini E, Quagliuolo V, Broto JM, Lopez Pousa A, Grignani G, Brunello A, Blay JY, Tendero O, Beveridge R, Ferraresi V, Lugowska I, Infante G, Braglia L, Merlo F, Fontana V, Marchesi E, Donati D, Palassini E, Bianchi G, Marrari A, Morosi C, **Stacchiotti S**,

Bagué S, Coindre J, Dei Tos AP, Picci P, Bruzzi P, Miceli R, Casali PG, Gronchi A. **Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: a sarculator-based risk stratification analysis of the randomised trial ISG:STS 1001**. Cancer 2021, in press.

11. Van De Sande M, Tap WD, Gelhorn HL, Ye X, Speck RM, Palmerini E, **Stacchiotti S**, Desai J, Wagner AJ, Alcindor T, Ganjoo K, Martin-Broto J, Wang Q, Shuster D, Gelderblom H, Healey JH. **Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial**. Acta Orthop. 2021, 92:493-499.
12. **Stacchiotti S**, Miah AB, Frezza AM, Messiou C, Morosi C, Caraceni A, Antonescu CR, Bajpai J, Baldini E, Bauer S, Biagini R, Bielack S, Blay JY, Bonvalot S, Boukovinas I, Bovee JVMG., Boye K, Brodowicz T, Callegaro D, De Alava E, Deoras-Sutliff M, Dufresne A, Eriksson M, Errani C, Fedenko A, Ferraresi V, A Ferrari, CDM Fletcher, X Garcia del Muro, H Gelderblom, RA. Gladdy, F Gouin, G Grignani, J Gutkovich, R Haas, N Hindi, P Hohenberger, P Huang, H Joensuu, RL Jones, C Jungels, B Kasper, A Kawai, A Le Cesne F Le Grange, A Leithner, H Leonard, A Lopez Pousa, J Martin Broto, O Merimsky, P Merriam, R Miceli, O Mir, M Molinari, M Montemurro, G Oldani, E Palmerini, MA Pantaleo, S Patel, S Piperno-Neumann, CP. Raut, V Ravi, ARA Razak, P Reichardt, BP Rubin, P Rutkowski, AA Safwat, C Sangalli, G Sapisochin, M Sbaraglia, S Scheipl, P Schöffski, D Strauss, SJ Strauss, K Sundby Hall, WD Tap, A Trama, A Tweddle, WTA van der Graaf, MAJ Van De Sande, W Van Houdt, G van Oortmerssen, AJ Wagner, M Wartenberg, J Wood, N Zaffaroni, C Zimmermann, Casali PG, Dei Tos AP, Gronchi A. **Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts**. ESMO open 2021, 6:100170.
13. Zanchetta E, Ciniselli CM, Bardelli A, Colombo C, **Stacchiotti S**, Baldi G, Provenzano S, Bertulli R, Bini F, Casale A, Greco FG, Ferrari A, Verderio P, Fiore M, Gronchi A, Casali PG, Morosi C, Palassini E. **Magnetic Resonance imaging patterns of tumor response to chemotherapy in desmoid-type fibromatosis**. Cancer Medicine 2021; 10:4356-4365.
14. Zucco V, Pasquali S, Tortoreto M, Brici S, Percio S, Dagrada G, Colombo C, Sanfilippo R; Lauricella C, Gounder M; El Bezawy R, Barisella M, Dei Tos AP, Casali PG, Gronchi A, **Stacchiotti S**, Zaffaroni N. **Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation** Journal of Experimental & Clinical Cancer Research 2021, 40:83.
15. Demetri GD, **Stacchiotti S**. **Contributions of Real-world Evidence and Real-world Data to Decision-making in the Management of Soft Tissue Sarcomas**. Oncology 2021; 99 Suppl 1:3-7.
16. Frezza AM, Napolitano A, Miceli R, Badalamenti G, Brunello A, Buonomenna C, Casali PG, Caraceni A, Grignani G, Gronchi A, Infante G, Morosi C, Saita L, Simeone N, Zaffaroni N, Vincenzi B, **Stacchiotti S**. **Clinical prognostic factors in advanced epithelioid haemangioendothelioma: a retrospective series within the Italian Rare Cancers Network**. ESMO open 2021; 6:100083.
17. Frezza AM, Ravi V, Lo Vullo S, Vincenzi B, Tolomeo F, Chen TWW, Teterycz P, Baldi GG, Italiano A, Penel N, Brunello A, Duffaud F, Hindi N, Iwata S, Smrke H, Fedenko A, Gelderblom H, Van Der Graaf W, Vozy A, Connolly E, Grassi M, Benjamin RS, Martin Broto J, Grignani G, Jones RL, Kawai A, Rutkowski P, Mariani L, Casali PG, **Stacchiotti S**. **Systemic therapies in advanced epithelioid haemangioendothelioma: a retrospective international case series from the World Sarcoma Network and a review of literature**. Cancer Med 2021; 10:2645-2659.
18. Lewis JH, Gelderblom H, van de Sande M, **Stacchiotti S**, Healey JH, Tap WD, Wagner AJ, Pousa AL, Druta M, Lin CC, Baba HA, Choi Y, Wang Q, Shuster DE, Bauer S. **Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors**. Oncologist. 2020; 26:e863-e873.
19. Swallow C, Strauss D, Bonvalot S, Rutkowski P, Desai A, Gladdy RA, Gonzalez R, Gyorki DE, Fairweather M, van Houdt WJ, Stoeckle E, Park JB, Albertsmeier M, Nessim C, Cardona K, Fiore M, Hayes A, Tzanis D, Skoczylas J, Ford SJ, Ng D, Mullinax JE, Snow H, Haas RL, Callegaro D, Smith MJ, Bouhadiba T, **Stacchiotti S**, Jones RL, DeLaney T, Roland CL, Raut CP, Gronchi A, on behalf of the Transatlantic Australasian RPS Working Group. **Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group**. Ann Surg Oncol 2021; 28:7873-7888.
20. Danieli M, Barretta F, Fiore M, Radaelli S, Sangalli C, Barisella M, **Stacchiotti S**, Palassini E, Miceli R, Callegaro D, Casali P, Gronchi A. **Unplanned excision of extremity and trunk wall soft tissue sarcoma: to re-resect or not to re-resect?** Ann Surg Oncology 2020; 28:4706-4717.
21. Simeone N, Frezza AM, Zaffaroni N, **Stacchiotti S**. **Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives**. Future Oncology 2020; 17:1253-1263.
22. **Stacchiotti S**, Simeone N, Lo Vullo S, Baldi GG, Brunello A, Vincenzi B, Palassini E, Dagrada GP, Collini P, Morosi C, Greco FG, Sbaraglia M, Dei Tos AP, Mariani L, Frezza AM, Casali PG. **Activity of sirolimus in patients with Progressive Epithelioid Hemangioendothelioma (EHE): a case-series analysis within the Italian Rare Cancer Network**. Cancer 2021; 127:569-576.
23. Martin-Broto J, Hindi N, Grignani G, Martinez-Trufero J, Redondo A, Valverde C, **Stacchiotti S**, Lopez-Pousa A, D'Ambrosio L, Gutierrez A, Perez-Vega H, Encinas-Tobajas V, de Alava E, Collini P, Peña-Chilet M, Dopazo J, Carrasco-Garcia I, Lopez-Alvarez M, Moura DS, Lopez-

Martin JA. **Nivolumab and Sunitinib combination in advanced soft-tissue sarcomas: a multicenter, single-arm, phase Ib/II trial.** J Immunother Cancer. 2020; 8:e001561.

24. Gelderblom H, Wagner AJ, Tap WD, Palmerini E, Wainberg ZA, Desai J, Healey JH, van de Sande M, Bernthal NM, Staals E, Peterfy C, Frezza AM, Hsu HH, Wang Q, Shuster DE, **Stacchiotti S. Long-Term Outcomes of Pexidartinib in Tenosynovial Giant Cell Tumors.** Cancer 2020; 27:884-893.
25. Haas RL, Walraven I, Lecointe-Artzner E, van Houdt WJ, Scholten AN, Strauss D, Schrage Y, Hayes AJ, Raut CP, Fairweather M, Baldini EH, Gronchi A, De Rosa L, Griffin AM, Ferguson PC, Wunder J, van de Sande MAJ, Krol ADG, Skoczylas J, Sangalli C, **Stacchiotti S. Management of Meningeal Solitary Fibrous Tumors / Hemangiopericytoma; surgery alone or surgery plus postoperative radiotherapy?** Acta Oncologica 2020; 60:35-41.
26. Yin O, Wagner AJ, Kang J, Knebel W, Zahir H, van de Sande M, Tap WD, Gelderblom H, Healey JH, Shuster D, **Stacchiotti S. Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor (TGCT) or Other Solid Tumors.** Journal Clinical Pharmacology 2020, 61:480-492.
27. Gounder M, Schöffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TWW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey J, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, **Stacchiotti S. Tazemetostat in advanced epithelioid sarcoma with INI1/SMARCB1 loss: Results from an international, open-label, phase 2 basket study.** Lancet Oncol 2020; 21:1423-1432.
28. **Stacchiotti S, Baldi GG, Morosi C, Gronchi A, Maestro R. Extraskelatal Myxoid Chondrosarcoma: State of the art and current research on biology and clinical management.** Cancers 2020; 12:2703.
29. Martin-Broto J, Lopez-Pousa A, Brohl AS, Van Tine BA, Powers B, **Stacchiotti S**, Blay JY, Hu J, Oakley III GJ, Wang H, Szpurka AM, Levy DE, Mo G, Ceccarelli M, Jones RL. **Circulating tumor cells and biomarker modulation with olaratumab monotherapy followed by olaratumab plus doxorubicin: phase 1b study in soft tissue sarcoma patients.** Molecular Cancer Ther 2021; 20:132-141.
30. Demetri GD, Antonescu CR, Bjerkehagen B, Bovée JVMG, Boye K, Chacón M, A.P. Dei Tos, J. Desai, J.A. Fletcher, H. Gelderblom, S. George, A. Gronchi, R.L. Haas, N. Hindi, P. Hohenberger, H. Joensuu, R.L. Jones, I. Judson, Y.-K. Kang, A. Kawai, A.J. Lazar, A. Le Cesne, R. Maestro, R.G. Maki, J. Martín, S. Patel, F. Penault-Llorca, C. Premanand Raut, P. Rutkowski, A. Safwat, M. Sbaraglia, I.-M. Schaefer, L. Shen, C. Serrano, P. Schöffski, **Stacchiotti S**, K. Sundby Hall, W.D. Tap, D.M. Thomas, J. Trent, C. Valverde, W.T.A. van der Graaf, M. von Mehren, A. Wagner, E. Wardelmann, Y. Naito, J. Zalcberg, J.-Y. Blay. **Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.** Ann Oncol 2020, 31:1506-1517.
31. Martin-Broto J, Hindi N, Aguiar S, Badilla-González R, Castro-Oliden V, Chacón M, Correa-Generoso R, de Álava E, Donati DM, Eriksson M, Falla-Jimenez M, German G, Gobo Silva ML, Gouin F, Gronchi A, Haro-Varas JC, Jiménez-Brenes N, Kasper B, Lopes de Mello CS, Maki R, Martínez-Delgado P, Martínez-Said H, Martínez-Tlahuel JL, Morales-Pérez JM, Muñoz-Casares FC, Nakagawa SA, Ortiz-Cruz EJ, Palmerini E, Patel S, Moura DS, **Stacchiotti S**, Sunyach MP, Valverde CM, Waisberg F, Blay JY. **Sarcome European and Latin American Network (SELNET) RECOMMENDATIONS ON PRIORITIZATION IN SARCOMA CARE DURING COVID-19 PANDEMIC.** The Oncologist 2020; 25:e1562-e157.
32. **Stacchiotti S, Baldi GG, Casali PG. Response to Patrick Schöffski's Letter to the Editor referencing The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis.** The Oncologist 2020; 25:e2018.
33. Raimondi A, Simeone N, Guzzo M, Maniezzo M, Collini P, Morosi C, Greco FG, Frezza AM, Casali PG, **Stacchiotti S. Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review.** ESMO Open 2020; 5:e000663.
34. Haas RLM, Trama A, **Stacchiotti S. Reply to Incidence of extrameningeal solitary fibrous tumors and Novel therapeutic approaches in the treatment of solitary fibrous tumors: A call for a combination therapy.** Cancer 2020; 126:4069-4070.
35. Paioli A, **Stacchiotti S**, Gronchi A. **ASO Author Reflections: Extraskelatal Myxoid Chondrosarcoma: A Rare Sarcoma Associated With Prolonged Survival.** Ann Surg Oncol. 2020; 27:797-798.
36. Baldi GG, Brahmi M, Lo Vullo S, Cojocar E, Mir O, Casanova M, Vincenzi B, De Pas T, Grignani G, Pantaleo MA, Blay JY, Jones RL, Le Cesne A, Frezza AM, Gronchi A, Collini P, Dei Tos AP, Morosi C, Mariani L, Casali PG **Stacchiotti S. The activity of chemotherapy in inflammatory myofibroblastic tumour (IMT): a multicentre, European retrospective case series analysis.** The Oncologist 2020; 25:e1777-e1784.
37. Gronchi A, Palmerini E, Quagliuolo V, Martin Broto J, Lopez Pousa A, Grignani G, Brunello A, Blay JY, Tendero O, Beveridge RD, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Braglia L, Donati DM, Palassini E, Bianchi G, Marrari A, Morosi C, **Stacchiotti S**, Bague S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Casali PG. **Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results**

of a Randomized Clinical Trial from the Italian Sarcoma Group, the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG) and the Polish Sarcoma Group (PSG). J Clin Oncol. 2020; 38:2178-2186.

38. Paioli A, **Stacchiotti S**, Campanacci D, Palmerini E, Frezza AM, Longhi A, Radaelli S, Donati DM, Beltrami G, Bianchi G, Barisella M, Righi A, Benini S, Fiore M, Picci P, Gronchi A **Extraskeletal myxoid chondrosarcoma with molecularly confirmed diagnosis: a multicentre retrospective study within the Italian Sarcoma Group.** Ann Surg Oncol 2020; 28:1142-1150.
39. Constantinidou A, Sauv  N, **Stacchiotti S**, Blay J-Y, Vincenzi B, Grignani G, Rutkowski P, Guida M, Hindi N, Klein A, Valentin T Sufiarsky J, Desai I, Steeghs N, Litiere S, Gelderblom H, Jones RL **An evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multi-center study.** ESMO Open 2020; 5:e000787.
40. Baldi G, Gronchi A, **Stacchiotti S.** **Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumours.** Expert Review of Clinical Pharmacology 2020, 13:571-576.
41. Radaelli S, Fossati P, Timmermann B, Boland P, Varga P, Kawai A, Reiko I, Bolle S, **Stacchiotti S**, Frezza AM, Sommer J,; Casali PG, De Laney T, Gronchi A. **The sacral chordoma margin.** European J Surg Oncol 2020, 46:1415-1422.
42. Frezza AM; Sbaraglia M; Lo Vullo S; Baldi GG, Simeone N, Frenos F, Campanacci D, **Stacchiotti S**, Pasquali S, Callegaro D, Gambarotti M, Barisella M, Palomba A, Mariani L, Casali PG, Dei Tos AP, Gronchi A. **The natural history of epithelioid sarcoma. A retrospective multicentre case-series within the Italian Sarcoma Group.** Eur J Surgical Oncology 2020; 46:1320-1326.
43. Martin-Broto J, Cruz J, Penel N, Lecesne A, Hindi N, Luna P, Moura DS, Bernabeu D, de Alava E, Lopez-Guerrero JA, Dopazo J, Pe a-Chilet M, Gutierrez A, Collini P, Karanian M, Redondo A, Lopez-Pousa A, Grignani G, Diaz-Martin J, Marcilla D, Fernandez-Serra A, Gonzalez-Aguilera C, Casali PG, Blay JY, **Stacchiotti S.** **Pazopanib for treatment of typical solitary fibrous tumor: a multicenter single-arm, phase II trial.** Lancet Oncol 2020, 21:456-466.
44. D'Ambrosio L, Touati N, Blay JY, Grignani G, Flippot R, Czarnicka AM, Piperno-Neumann S, Martin-Broto J, Sanfilippo R, Katz D, Duffaud F, Vincenzi B, Kasper B, Stark D, Mazzeo F, Tuchscherer A, Chevreau C, Sherriff J, Estival A, Liti re S, Sents W, **Stacchiotti S**, Gelderblom H, Gronchi A. **Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as first-line treatment for advanced leiomyosarcoma: a propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.** Cancer 2020, 126:2637-2647.
45. **Stacchiotti S**, Zuco V, Tortoreto M, Cominetti D, Frezza AM, Percio S, Indio V, Barisella M, Monti V, Brich S, Astolfi A, Colombo C, Pasquali S, Folini M, Gounder MM, Pantaleo MA, Collini P, Dei Tos AP, Casali PG, Gronchi A, Zaffaroni N. **Comparative Assessment of Antitumor Effects and Autophagy Induction as a Resistance Mechanism by Cytotoxics and EZH2 Inhibition in INI1-Negative Epithelioid Sarcoma Patient-Derived Xenograft.** Cancers 2019, 11(7).
46. Callegaro D, Miceli R, Bonvalot S, Ferguson PC, Strauss DC, van Praag VVM, Levy A, Griffin AM, Hayes AJ, **Stacchiotti S**, Le P choux C, Smith JM, Fiore M, Dei Tos AP, Smith HG, Catton C, Szkandera J, Leithner A, van de Sande MAJ, Casali PG, Wunder JS, Gronchi A. **Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma patients treated with surgery.** EClinicalMedicine 2020, 17:100215.
47. Desmoid Tumor Working Group. **The management of desmoid tumors: a joint global consensus-based guidelines approach for adult and pediatric patients.** Eur J Cancer 2020, 127:96-107.
48. Napolitano A, Provenzano S, Colombo C, Vitellaro M, Brunello A, Badalamenti G, Nannini M, Ibrahim T, Hohenberger P, Gasperoni S, Gennatasi S, Jones RJ, Hindi N, Martin Broto J, Spalato Ceruso M, Silletta M, Dei Tos AP, Gronchi A, **Stacchiotti S**, Santini D, Tonini G, Palassini E, Vincenzi B. **FAP-related desmoid tumors treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis.** ESMOopen 2020, pii: e000604. doi: 10.1136/esmoopen-2019-000604.
49. Verspoor FGM, Mastboom MJL, Hannink G, Maki RG, Wagner A, Bompas E, Desai J, Italiano A, Seddon BM, van der Graaf WTA, Blay JY, Brahmi M, Eberst L, **Stacchiotti S**, Mir O, van de Sande MAJ, Gelderblom H, Cassier PA. **Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor.** Scientific Reports 2019, 9:14551.
50. Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, Alcindor T, Ganjoo K, Mart n-Broto J, Ryan CW, Thomas DM, Peterfy C, Healey JH, van de Sande M, Gelhorn HL, Shuster DE, Wang Q, Yver A, Hsu HH, Lin PS, Tong-Starksen S, **Stacchiotti S**, Wagner AJ; ENLIVEN investigators. **Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.** Lancet. 2019, 394:478-487.
51. Scanagatta P, Furia S, Pardolesi A, Rolli L, Fabbri A, **Stacchiotti S**, Pastorino U. **Worsening hemoptysis in a rare intrapulmonary triton tumor mimicking lung cancer.** Ann Thorac Surg. 2020, 109(3):e199-e201.

52. Brich S, Bozzi F, Perrone F, Tamborini E, Cabras AD, Deraco M, **Stacchiotti S**, Dagrada GP, Pilotti S. **Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.** *Mod Pathol* 2020, 33:217-227.
53. Frezza AM, Assi T, Lo Vullo S, Ben-Amy E, Dufresne A, Yonemori K, Noguchi E, Siontis B, Ferraro R; Tetrycz P, Duffaud F, Ravi V, Vincenzi B, Gelderblom H, Pantaleo MA, Baldi GG, Desar I, Fedenko A, Maki R, Jones R, Benjamin R Blay JY, Kawai A, Gounder M, Gronchi A, Le Cesne A, Mir O, Czarnecka A, Schuetze S, Wagner AJ, Adam J, Barisella M, Sbaraglia M, Hornick JL, Meurgey A, Mariani L, Casali PG, Thornton K, **Stacchiotti S**. **Systemic treatments in MDM2 positive intimal sarcoma: a multicentre experience with anthracycline, gemcitabine and pazopanib within the World Sarcoma Network (WSN).** *Cancer* 2020, 126:98-104.
54. **Stacchiotti S**, Ferrari S, Redondo A, Hindi-Muniz N, Palmerini E, Vaz Salgado MA, Frezza AM, Casali PG, Gutierrez A, Lopez-Pousa A, Grignani G, Italiano A, LeCesne A, Dumont S, Blay JY, Penel N, Bernabeu D, de Alava E, Karanian M, Morosi C, Brich S, Dagrada GP, Vallacchi V, Castelli C, Brenca M, Racanelli D, Maestro R, Collini P, Cruz J, Martin-Broto J. **Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial.** *Lancet Oncol* 2019, 20:1252-1262.
55. Pasquali S, **Stacchiotti S**. **Cediranib for alveolar soft part sarcoma: a randomised study in relation to clinical practice.** *Lancet Oncol.* 2019, 20:901-903.
56. Nizri E, Fiore M, Barretta F, Colombo C, Radaelli S, Callegaro D, Sanfilippo R, Sangalli C, Collini P, **Stacchiotti S**, Casali PG, Miceli R, Gronchi A. **Intraperitoneal invasion of retroperitoneal sarcomas- a risk factor for dismal prognosis** *Ann Surg Oncol* 2019, 26:3535-3541.
57. Sanfilippo R, Jones R, Blay JY, Le Cesne A, Provenzano S, Antoniou G, Mir O, Fucà G, Fumagalli E, Bertulli R, **Stacchiotti S**, Brahmi M, Grosso F, Dufresne A, Hindi N, Sbaraglia M, Gronchi A, Collini P, Dei Tos AP, Casali PG. **Role of chemotherapy, VEGFR inhibitors and mTOR Inhibitors in advanced Perivascular Epithelioid Cell Tumours (PEComas).** *Clinical Cancer Res* 2019, 25:5295-5300.
58. Brenca M, **Stacchiotti S**, Fassetta K, Polano M, Janjusevic M, Racanelli D, Sbaraglia M, Rossi S, Brich S, Dagrada GP, Collini P, Colombo C, Gronchi A, Astolfi A, Indio V, Pantaleo MA, Picci P, Casali PG, Dei Tos AP, Pilotti S, R Maestro. **NR4A3 fusion proteins trigger an axon guidance switch that marks the difference between EWSR1 and TAF15 translocated extraskeletal myxoid chondrosarcomas.** *Journal of Pathology* 2019, 249:90-101.
59. Pantaleo MA, Tarantino G, Agostinelli C, Urbini M, Nannini M, Saponara M, Castelli C, **Stacchiotti S**, Fumagalli E, Gatto L, Santini D, De Leo A, Sabattini A, Pession A, Ardizzoni A, Indio V, Astolfi A. **Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response.** *OncolImmunology.*2019, 8(9).
60. Mastboom MJL, Staals EL, Verspoor FGM, Rueten-Budde AJ, **Stacchiotti S**, Palmerini E, Schaap GR, Jutte PC, Aston W, Leithner A, Dammerer D, Takeuchi A, Thio Q, Niu X, Wunder JS, TGCT study group, van de Sande MAJ. **Surgical Treatment of localized-type tenosynovial giant cell tumours of large joints.** *Journal of Bone & Joint Surgery* 2019, 101:1309-1318.
61. Ferraris M, Callegaro D, Barretta F, Fiore M, Radaelli S, **Stacchiotti S**, Miceli R, Socrate AM, Locati P, Gronchi A. **Outcome of ilioacaval resection and reconstruction for retroperitoneal sarcoma.** *J Vasc Surg Venous Lymphat Disord.* 2019, 7:547-556.
62. **Stacchiotti S**, Simeone N, Lo Vullo S, Morosi C, Greco FG, Gronchi A, Barisella M, Collini P, Zaffaroni N, Dagrada GP, Frezza AM, Mariani L, Casali PG. **Activity of axitinib in progressive advanced solitary fibrous tumor: results from an exploratory, investigator-driven Phase 2 clinical study.** *European Journal of Cancer* 2019, 106:225-233.
63. Mastboom MJL, Palmerini E, Verspoor FGM, Rueten-Budde AJ, Stacchiotti S, Staals EL, Schaap PC Jutteh GR, AstonW, Gelderblom H, Leithner A, Dammerer D, Takeuchi A, Thio Q, Niu X, Wunder JS, TGCT-study group*, van de Sande MJA. **Surgical treatment of patients with diffuse-type tenosynovial giant-cell tumours: an individual patient data meta-analysis** *Lancet Oncol* 2019, 20:877-886.
64. Pasquali S, Pizzamiglio S, Touati N, Litiere S, Marraud S, Kasper B, Gelderblom H, **Stacchiotti S**, Judson I, Dei Tos AP, Verderio P, Casali PG, Woll PJ, Gronchi A, on behalf of the EORTC – Soft Tissue and Bone Sarcoma Group. **The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.** *Eur J Cancer.* 2019; 109:51-60.
65. Frezza AM, Botta L, Trama A, Dei Tos AP, **Stacchiotti S** and RARECARE Working Group. **Chordoma: update on pathology, epidemiology, biology and medical therapies.** *Curr Opin Oncol.* 2019; 31:114-120..
66. Nizri E, Fiore M, Colombo C, Radaelli S, Callegaro D, Sanfilippo R, Sangalli C, Collini P, Morosi C, **Stacchiotti S**, Casali PG, Gronchi A. **Completion surgery of residual disease after primary inadequate surgery of retroperitoneal sarcomas achieves comparable oncological outcomes- a propensity score analysis.** *J Surg Oncol.* 2019; 119:318-323.

67. Devecchi A, De Cecco L, Dugo M, Penso D, Dagrada G, Brich S, **Stacchiotti S**, Sensi M, Canevari S, Pilotti S. **The genomics of desmoplastic small round cell tumour reveals the profound deregulation of genes related to DNA damage response, RNA binding proteins and epithelial mesenchymal transition.** *Cancer Communications* 2018, 38(1):70.
68. **Stacchiotti S**, Morosi C, Lo Vullo S, Casale A, Palassini E, Frezza A, Dinoi G, Messina A, Gronchi A, Cavalleri A, Venturelli E, Morelli D, Pilotti S, Collini P, Brich S, Tamborini E, Mariani L, Casali PG. **Imatinib and everolimus in patients with progressing advanced chordoma: a Phase II clinical study.** *Cancer* 2018, 124:4056-4063.
69. Giannini L, Incandela F, Fiore M, Gronchi A, **Stacchiotti S**, Sangalli C, Piazza C. **Radiation-Induced Sarcoma of the Head and Neck: A Review of the Literature.** *Front Oncol.* 2018; 17:8:449.
70. Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brennan B, Brodowicz T, Broto JM, Brugières L, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Dhooge C, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gaspar N, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hecker-Nolting S, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kager L, Kasper B, Kopeckova K, Krákorová DA, Ladenstein R, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Morland B, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, **Stacchiotti S**, Strauss SJ, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee, PaedCan and ERN EURACAN. **Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.** *Ann Oncol.* 2018; 29(Supplement_4):iv79-iv95.
71. Callegaro D, Miceli R, Bonvalot S, Ferguson P, Strauss DC, Levy A, Griffin A, Hayes AJ, **Stacchiotti S**, Le Pèchoux C, Smith MJ, Fiore M, Dei Tos AP, Smith HG, Catton C, Casali PG, Wunder JS, Gronchi A. **Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centers.** *Eur J Cancer* 2018, 105:19-27.
72. Martin-Broto J, **Stacchiotti S**, Lopez-Pousa A, Redondo A, Bernabeu D, de Alava E, Casali PG, Italiano A, Gutierrez A, Moura DS, Peña M, Diaz-Martin J, Biscuola M, Taron M, Collini P, Ranchere-Vince D, Garcia del Muro X, Grignani G, Dumont S, Martinez-Trufero J, Palmerini E, Hindi N, Sebio A, Dopazo J, LeCesne A, Blay JY, Cruz J. **Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.** *Lancet Oncol* 2018, 20:134-144.
73. Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, **Stacchiotti S**, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN. **Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.** *Ann Oncol.* 2018; 29(Supplement_4):iv267
74. Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, **Stacchiotti S**, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN. **Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.** *Ann Oncol.* 2018; 29(Supplement_4):iv268-iv269..
75. Tazzari M, Brich S, Tuccitto A, Bozzi F, Beretta V, Spagnuolo R, Negri T, **Stacchiotti S**, Deraco M, Baratti D, Camisaschi C, Villa A, Vergani B, Rivoltini L, Pilotti S, Castelli C. **Complex immune contextures characterise malignant peritoneal mesothelioma: loss of adaptive immunological signature in the more aggressive histological types.** *J Immunol Res.* 2018; 2018:5804230.
76. Urbini M, Indio V, Astolfi A, Tarantino G, Renne SL, Pilotti S, Dei Tos AP, Maestro R, Collini P, Nannini M, Saponara M, Murrone L, Dagrada GP, Colombo C, Gronchi A, Pession A, Casali PG, **Stacchiotti S**, Pantaleo M. **Identification of an actionable mutation of KIT in a case of extraskeletal myxoid chondrosarcoma.** *International Journal of Molecular Sciences* 2018;19:7.
77. Grignani G, D'Ambrosio L, Pignochino Y, Palmerini E, Zucchetti M, Boccone P, Aliberti S, **Stacchiotti S**, Bertulli R, Piana R, Miano S, Tolomeo F, Chiabotto G, Sangiolo D, Pisacane A, Dei Tos AP, Novara L, Bartolini A, Marchesi E, D'Incalci M, Bardelli A, Picci P, Ferrari S, Aglietta M. **Trabectedin and olaparib in patients with advanced and non-resectable bone and soft tissue sarcomas (TOMAS trial): a phase 1b study from the Italian Sarcoma Group.** *Lancet Oncol* 2018, 19:1360-1371.

78. Colombo C, Urbini M, Astolfi A, Collini P, Indio V, Belfiore A, Paielli N, Perrone F, Tarantino G, Palassini E, Fiore M, Pession A, **Stacchiotti S**, Pantaleo MA, Gronchi A. **Novel intra-genic large deletions of CTNNB1 gene identified in WT desmoid-type fibromatosis.** *Genes Chromosomes Cancer.* 2018; 57:495-503.
79. Schöffski P, Wozniak A, Kasper B, Aamdal S, Leahy MG, Rutkowski P, Bauer S, Gelderblom H, Italiano A, Lindner LH, Hennig I, Strauss S, Zakotnik B, Anthony A, Albiges L, Blay JY, Reichardt P, Sufliarsky J, van der Graaf WTA, Debiec-Rychter M, Sciort R, Van Cann T, Marréaud S, Raveloarivahy T, Collette S, **Stacchiotti S.** **Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3.** *European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 "CREATE".* *Ann Oncol* 2018, 29:758-765.
80. Haas RL, Walraven I, Lecointe-Artzner E, Scholten A, Griffin AM, Ferguson PC, Miah AB, Zaidi S, DeLaney TF, Chen YL, Spalek M, Krol ADG, Moeri-Schimmel RG, van de Sande MAJ, Sangalli C, **Stacchiotti S.** **Radiotherapy as sole management for Solitary Fibrous Tumours (SFT): a retrospective study from the Global SFT Initiative in collaboration with the Sarcoma Patients EuroNet.** *International Journal of Radiation Oncology, Biology, Physics* 2018; 101:1226-1233.
81. Raimondi A, Colombo F, Pintarelli G, Morosi C, Renne SL, Frezza AM, Saponara M, Dei Tos AP, Mazzocchi A, Provenzano S, Casali PG, **Stacchiotti S.** **Prolonged activity and toxicity of sirolimus in a patient with metastatic renal PEComa: a case report and literature review.** *Anticancer drugs* 2018, 29:589-595.
82. Rutkowski P, Gaston L, Borkowska A, **Stacchiotti S**, Gelderblom H, Baldi GG, Palmerini E, Casali PG, Gronchi A, Parry M, Ferrari S, Dijkstra S, Pieńkowski A, Grimer R. **Denosumab treatment of inoperable or locally advanced Giant Cell Tumor of Bone - multicenter analysis outside clinical trial.** *Eur J Surg Oncol.* 2018; 44:1384-1390.
83. Schöffski P, Sufliarsky J, Gelderblom HA, Blay JY, Strauss S, **Stacchiotti S**, Rutkowski P, Lindner LH, Leahy MG, Italiano A, Isambert N, Debiec-Rychter M, Sciort R, Van Cann T, Marréaud S, Nzokirantevye A, Collette S, Wozniak A. **Prospective, non-randomized, multicenter, phase 2 trial of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumor with and without anaplastic lymphoma kinase gene alterations: EORTC study 90101 CREATE.** *Lancet Respiratory Medicine* 2018, 6:431-441.
84. Management of metastatic retroperitoneal sarcoma: a consensus approach from the Transatlantic Retroperitoneal Sarcoma Working Group (TARPSWG). *Ann Oncol* 2018, 29:857-871.
85. Frezza AM, Jones RL, Lo Vullo S, Asano N, Lucibello F, Ben-Ami E, Ratan R, Teterycz P, Boye K, Brahma M, Palmerini E, Fedenko A, Vincenzi B, Brunello A, Desar IME, Benjamin RS, Blay JY, Martin Broto J, Casali PG, Gelderblom H, Grignani G, Gronchi A, Hall KS, Mir O, Rutkowski P, Wagner AJ, Anurova O, Collini P, Dei Tos AP, Flucke U, Hornick JL, Lobmaier I, Philippe T, Picci P, Ranchere D, Renne RL, Sbaraglia M, Thway K, Wagrodzki M, Wang WL, Yoshida A, Mariani L, Kawai A, **Stacchiotti S.** **Anthracycline, gemcitabine and pazopanib in epithelioid sarcoma: results of a retrospective multi-institutional case series.** *JAMA Oncol.* 2018; 4:e180219.
86. Gelderblom H, Cropet C, Chevreau C, Boyle R, Tattersall M, **Stacchiotti S**, Italiano A, Piperno-Neumann S, Le Cesne A, Ferraresi V, Penel N, Duffaud F, Cassier PA, Toulmonde M, Casali PG, Taieb S, Guillemaut S, Metzger S, Pérol D, Blay JY, **Tumor control with nilotinib in locally advanced pigmented villonodular synovitis (PVNS) / diffuse-type giant cell tumour (dtTGCT): a phase II study,** *Lancet Oncology* 2018, 19:639-648.
87. Pasquali S; Colombo C, Pizzamiglio S, Verderio P, Callegaro D, **Stacchiotti S**, Martin Broto J, Lopez-Pousa A, Ferrari S, Poveda A, De Paoli A, Quagliuolo V, Cruz Jurado J; Comandone A, Grignani G, De Sanctis R, Palassini E, Llomboart-Bosch A, Dei Tos AP, Casali PG, Picci P, Gronchi A. **High-risk soft tissue sarcomas treated with perioperative chemotherapy: improving prognostic classification in a randomized clinical trial.** *European Journal Of Cancer* 2018; 93:28-36.
88. Magnaghi P, Salom B, Cozzi L, Amboldi N, Ballinari N, Tamborini E, Gasparri F, Montagnoli A, Radrizzani L, Somaschini A, Bosotti R, Orrenius C, Bozzi F, Pilotti S, Galvani A, Sommer J, **Stacchiotti S**, Isacchi A. **Afatinib is a new therapeutic approach in chordoma with a unique ability to target EGFR and Brachyury.** *Mol Cancer Ther* 2017, 17:603-613.
89. Rothermundt C, Pestel GF, Bauer S, Blay JY, Grünwald V, Italiano A, Kasper B, Kollar A, Lindner LH, Miah A, Sleijfer S, **Stacchiotti S**, Putora PM. **Pre- And Postoperative Chemotherapy in Localized Extremity Soft Tissue Sarcoma - an EORTC Expert Survey.** *The Oncologist* 2017; 23:461-467.
90. **Stacchiotti S**, Van Tie AB **Synovial Sarcoma: current concepts and future perspectives.** *JCO* 2017, 36:180-187.
91. Schöffski P, Wozniak A, **Stacchiotti S**, Rutkowski P, Blay JY, Lindner LH, Strauss SJ, Anthony A, Duffaud F, Richter S, Grünwald V, Leahy MG, Reichardt P, Sufliarsky J, van der Graaf WT, Sciort R, Debiec-Rychter M, van Cann T, Marréaud S, Lia M, Raveloarivahy T, Collette L, Bauer S. **Activity and safety of crizotinib in patients with advanced clear cell sarcoma with MET alterations.** *European Organization for Research and Treatment of Cancer phase 2 trial 90101 "CREATE".* *Ann Oncol.* 2017; 28:3000-3008.
92. Colia V, Fumagalli E, Provenzano S, Bertulli R, **Stacchiotti S**, Morosi C, Collini P, Gronchi A, Casali PG, Sanfilippo R. **High-dose Ifosfamide chemotherapy in a series of patients affected by myxoid liposarcoma.** *Sarcoma* 2017; doi: 10.1155/2017/3739159.

93. Bosotti R, Magnaghi P, Di Bella S, Cozzi L, Cusi C, Bozzi F, Beltrami N, Carapezza G, Ballinari D, Amboldi N, Lupi R, Somaschini A, Radrizzani L, Salom B, Galvani A, **Stacchiotti S**, Tamborini E, Isacchi A. **Establishment and genomic characterization of the new chordoma cell line Chor-IN-1**. Scientific Reports 2017; 7:9226.
94. Vincenzi B, **Stacchiotti S**, Collini P, Pantano F, Rabbitt C, Perrone G, Iuliani F, Baldi A, Badalamenti G, Sanfilippo R, Santini D, Onetti Muda A, Gronchi A, Casali PG, Dei Tos A, Tonini G. **Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma**. Br J Cancer 2017; 117:340-346.
95. Colia V, **Stacchiotti S**. **Medical treatment of advanced chordomas**. Eur J Cancer 2017, 83:220-228.
96. **Stacchiotti S**, Mir O, Le Cesne A, Vincenzi B, Fedenko A, Maki RG, Somaiah N, Patel S, Brahmi M, Blay JY, Boye K, Sundby Hall K, Gelderblom H, Hindi N, Martin-Broto J, Kosela H, Rutkowski P, Italiano A, Duffaud F, Kobayashi E, Casali PG, Provenzano S, Kawai A. **Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma (ASPS)**. The Oncologist 2017; 23:62-70.
97. Kasper B, Baumgarten C, Garcia J, Bonvalot S, Haas R, Haller F, Hohenberger P, Penel N, Messiou C, van der Graaf WT, Gronchi A on behalf of the Desmoid Working Group. **An update on the management of sporadic desmoid-type fibrosis: a European consensus initiative between sarcoma patients EURONET (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC) / Soft Tissue and Bone Sarcoma Group (STBSG)**. Ann Oncol 2017, 28:2399-2408.
98. Urbini M, Astolfi A, Pantaleo, Serravalle S, Dei Tos AP, Picci P, Indio V, Sbaraglia M, Benini S, Righi A, Gambarotti M, Gronchi A, Colombo C, Dagrada GP, Pilotti S, Maestro R, Polano M, Saponara M, Tarantino G, Pession A, Biasco G, Casali PG, **Stacchiotti S**. **HSPA8 as a novel fusion partner of NR4A3 in extraskeletal myxoid chondrosarcoma: a case report**. Gene Chrom and Cancer 2017, 56:582-586.
99. Frezza AM, **Stacchiotti S**, Gronchi A. **Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new**. BMC Medicine 2017; 15:109.
100. Colombo C, Belfiore A, Paielli N, De Cecco L, Canevari S, Laurini E, Fermeiglia M, Prici S, Verderio P, Bottelli S, Fiore M, **Stacchiotti S**, Palassini E, Gronchi A, Pilotti S, Perrone F. **β -Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression**. Mol Oncol. 2017; 11:1495-1507.
101. Frezza AM, Stacchiotti S, Gronchi A. Highlights in soft tissue sarcomas and gastrointestinal stromal tumours (GIST) trials reported at ASCO 2017 Annual Meeting. BMC Med. 2017; 15:160.
102. Martin-Broto J, Reichardt P, **Stacchiotti S**, Blay JY. **Review of past and present clinical cases with a view to future treatment options**. Future Oncology 2017; 13:11-28.
103. Urbini M, Astolfi A, Indio V, Serravalle S, Gronchi A, Fiore M, Maestro R, Brenca M, Dei Tos AP, Dagrada GP, Negri T, Pilotti S, Casali PG, Pession A, **Stacchiotti S**, Pantaleo MA. **Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue**. Oncotarget 2017; 8:60036-60045.
104. Pasquali S, Palassini E, **Stacchiotti S**, Casali PG, Gronchi A. **Neoadjuvant treatment: a novel standard?** Current Opinion in Oncology, 2017; 29:253-259.
105. Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Lopez Pousa A, Grignani G, Basso U, Blay JY, Tendero O, Beveridge RD, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi M, Donati DM, Palassini E, Palmerini E, De Sanctis R, Morosi C, **Stacchiotti S**, Bague S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, PG Casali. **Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-ST5 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial**. Lancet Oncol 2017, 18:812-822.
106. Negri T, Bric S, Bozzi F, Volpi C, Gualeni AV, **Stacchiotti S**, De Cecco L, Canevari S, Gloghini A, Pilotti S. **New transcriptional-based insights into the pathogenesis of desmoplastic small round cell tumors (DSRCTs)**. Oncotarget 2017, 8:32492-32504.
107. **Stacchiotti S**, Gronchi A, Fossati P, Akiyama T, Alapetite C, Baumann M, Blay JY, Bolle S, Boriani S, Bruzzi P, Capanna R, Caraceni A, Casadei R, Colia V, Debus J, Delaney T, Desai A, Dileo P, Dijkstra S, Doglietto F, Flanagan A, Froelich S, Gardner PA, Gelderblom H, Gokaslan ZL, Haa S R, Heery C, Hindi N, Hohenberger P, Hornicek F, Imai R, Jeys L, Jones RL, Kasper B, Kawai A, M. Krengh P, Leithner A, Logowska I, Martin Broto J, D. Mazzatenta D, Morosi C, Nicolai P, Norum OJ, S. Patel S, Penel N, Picci P, Pilotti S, Radaelli S, Ricchini F, Rutkowski P, Scheipl S, Sen C, Tamborini T, Thornton K, Timmermann B, Torri V, Tunn PU, Uhl M, Yamada Y, Weber DC, Vanel D, Varga PP, LA Vleggeert-Lankamp C, Casali PG, Sommer J. **Best practices for the Management of Local-regional Recurrent Chordoma. A Position Paper by the Chordoma Global Consensus Group**. Annals of Oncology 2017, 28: 1230–1242,.
108. **Stacchiotti S**, Saponara M, Frapolli R, Tortoreto M, Cominetti D, Provenzano S, Negri T, Dagrada GP, Gronchi A, Colombo C, Vincenzi B, Badalamenti G, Zuco V, Renne SL, Collini P, Morosi C, Dei Tos AP, Bello E, Pilotti S, Casali PG, D'Incalci M, Zaffaroni N. **Patient-derived**

solitary fibrous tumor xenografts predict high sensitivity to doxorubicin/ dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumor. Eur J Cancer 2017, 76:84-92..

109. Marchesi E, Cagnazzo C, Quattrini I, Piccini Leopardi M, Villa C, Grignani G, D'Ambrosio L, **Stacchiotti S**, Casali PG, Picci P. **How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience.** Clin Sarc Res 2017; 7:4.
110. Pantaleo MA, Urbini M, Indio V, Ravegnini G, Nannini M, De Luca M, Tarantino G, Angelini S, Gronchi A, Vincenzi B, Grignani G, Colombo C, Fumagalli E, Gatto L, Saponara M, Ianni M, Paterini P, Santini D, Pirini MG, Ceccarelli C, Altimari, Gruppioni E, Renne SL, Collini P, **Stacchiotti S**, Brandi G, Casali PG, D Pinna A, Astolfi A, Biasco G. **Genome-wide Analyses Identifies MEN1 and MAX Mutations and a Neuroendocrine-like Molecular Heterogeneity in Quadruple WT GIST.** Molecular Cancer Ther 2017, 15:553-562.
111. Saponara MS, **Stacchiotti S**, Gronchi A. **Pharmacological therapies for Liposarcoma.** Expert Review of Clinical Pharmacology 2017; 10:361-377.
112. Kollár A, Jones RL, **Stacchiotti S**, Gelderblom H, Guida M, Grignani G, Steeghs N, Safwat A, Katz D, Duffaud F, Sleijfer S, van der Graaf W, Touati N, Litière S, Marreaud S, Gronchi A, Kasper B. **Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.** Acta Oncologica 2017; 56:88-92.
113. Palassini E, Frezza AF, Mariani L, Lalli L, Colombo C, Fiore M, Messina A, Casale A, Morosi C, Collini P, **Stacchiotti S**, Casali PG, Gronchi A. Long-term efficacy of methotrexate plus vinblastine/vinorelbine in large series of patients affected by desmoid-type fibromatosis. The Cancer Journal 2017, 23: 86-91.
114. Saponara MS, **Stacchiotti S**, Casali PG, Gronchi A. (Neo)adjuvant treatment in localized soft tissue sarcoma (STS): the unsolved affair. Eur J Cancer 2017; 70:1-11..
115. Gaston CL, Grimer RJ, Parry M, **Stacchiotti S**, Dei Tos AP, Gelderblom H, Ferrari S, Baldi GG, Jones RL, Chawla S, Casali P, LeCesne A, Blay JY, Dijkstra SP, Thomas DM, Rutkowski P. **Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone.** Clin Sarcoma Res. 2016; 6(1):15. doi: 10.1186/s13569-016-0056-0.
116. Gronchi A, **Stacchiotti S**, Verderio P, Ferrari S, Martin Broto J, Lopez-Pousa A, Llombart-Bosch A, Dei Tos AP, Collini P, Cruz Jurado J, De Paoli A, Donati DM, Poveda A, Quagliuolo V, Comandone A, Grignani G, Morosi C, Messina A, De Sanctis R, Bottelli R, Palassini E, Casali PG, Picci P. **Short, Full-Dose Adjuvant Chemotherapy (CT) in High-Risk Adult Soft Tissue Sarcomas (STS): Long term Follow-Up of a Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma Group.** Ann Oncol 2016; 27:2283-2288.
117. Colia V, Provenzano S, Morosi C, Collini P, Renne SL, Dagrada GP, Sangalli S, Dei Tos AP, Marrari A, Casali PG, **Stacchiotti S**. **Solitary Fibrous tumour presenting with a single bone metastasis: report of six cases and literature review.** Clinical Sarcoma Research 2016; 6:16.
118. **Stacchiotti S**, Astolfi A, Gronchi A, Fontana A, Pantaleo MA, Negri T, Brenca M, Tazzari M, Urbini M, Indio V, Colombo C, Radaelli S, Brich S, Dei Tos AP, Casali PG, Castelli C, Dagrada GP, Pilotti S, Maestro R. **Evolution of Dermatofibrosarcoma protuberans (DFSP) to DFSP-derived fibrosarcoma (FS-DFSP): an event marked by epithelial mesenchymal transition-like process and 22q loss.** Mol Cancer Res 2016; 14:820-9.
119. Tazzari M, Indio V, Vergani B, De Cecco L, Rini F, Negri T, Camisaschi C, Fiore M, **Stacchiotti S**, Dagrada P, Casali GP Gronchi A, Astolfi A, Pantaleo M, Villa A, Lombardo C, Arienti F, Pilotti S, Rivoltini L, Castelli C. **Adaptive immunity in fibrosarcomatous dermatofibrosarcoma protuberans and response to imatinib treatment.** Journal of Investigative Dermatology 2017; 137:484-493.
120. Collini P, Barisella M, Renne S, Pizzi N, Mattavelli D, **Stacchiotti S**, Mattavelli F. **Epithelioid angiosarcoma of the thyroid gland without distant metastases at diagnosis: report of 6 cases with a long follow-up.** Virchows Archiv 2016; 469:223-32.
121. Callegaro D, Miceli R, Bonvalot S, Ferguson P, Strauss DC, Antonin Levy A, Griffin A, Hayes AJ, **Stacchiotti S**, Le Pechoux C, Smith MJ, Fiore M, Dei Tos AP, Smith HG, Mariani L, Wunder JS, Pollock RE, Casali PG, Gronchi A. **Development and external validation of two nomograms to predict overall survival and distant metastases after surgical resection of localised soft tissue sarcomas of the extremities: a retrospective analysis.** Lancet Oncol 2016; 17:671-80.
122. Radaelli S, Fiore M, Colombo C, Ford S, Palassini E, Sanfilippo R, **Stacchiotti S**, Sangalli C, Morosi C, Casali PG, Gronchi A. **Vascular resection en-bloc with tumor removal and graft reconstruction is safe and effective in soft tissue sarcoma (STS) of the extremities and retroperitoneum.** Surgical Oncol 2016; 25: 125-31.
123. Trans-Atlantic RPS Working Group members. **Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult. A Consensus Approach from the Trans-Atlantic RPS Working group (TARPSWG).** Ann Surg Oncol. 2016; 23:3531-40..

124. **Stacchiotti S**, Provenzano S, Dagrada G, Negri T, Brich S, Basso U, Brunello A, Grosso F, Galli L, Palassini E, Libertini M, Colia V, Gronchi A, Dei Tos AP, Crippa F, Morosi C, Pilotti S, Casali PG. **Sirolimus in advanced epithelioid hemangioendothelioma: a retrospective case series analysis from the Italian Rare Cancer Network database.** *Ann Surg Oncol* 2016; 23: 361-9.
125. Pasquali S, Gronchi A, Strauss D, Bonvalot S, Jeys L, **Stacchiotti S**, Hayes A, Honore C, Collini P, Renne SL, Alexander N, Grimer RJ, Callegaro D, Sumathi VP, Gourevitch D, Desai A. **Resectable extra-pleural and extra-meningeal solitary fibrous tumours: A multi-centre prognostic study.** *Eur J Surg Oncol.* 2016; 42:1064-70.
126. Spagnuolo RD, Brich S, Bozzi F, Conca E, Castelli C, Tazzari M, Maestro R, Brenca M, Gloghini A, **Stacchiotti S**, Pierotti MA, Pilotti S, Negri T. **Sunitinib-induced morpho-functional changes and drug effectiveness in malignant solitary fibrous tumours.** *Oncotarget* 2016, in press.
127. Colia V, Provenzano S, Casali PG, **Stacchiotti S.** **Systemic therapy for selected skull base sarcomas: chondrosarcoma, chordoma, giant cell tumour and solitary fibrous tumor/ hemangiopericytoma.** *Rep Pract Oncol Radiother* 2016; 21:361-9.
128. Radaelli S, Stacchiotti S, Ruggieri P, Donati D, Casali PG, Palmerini E, Collini P, Gambarotti M, Porcu L, Boriani S, Gronchi A, Picci P. **Sacral chordoma: long-term outcome of a large series of patient surgically treated at two reference centers.** *Spine*, 2016; 41:1049-57.
129. Saponara M, **Stacchiotti S**, Gronchi A. **The safety and efficacy of Trabectedin for the treatment of liposarcoma or leiomyosarcoma.** *Expert Rev Anticancer Ther.* 2016; 16:473-84.
130. **Stacchiotti S**, Pantaleo MA, Negri T, Astolfi A, Tazzari M, Dagrada GP, Urbini M, Indio V, Maestro R, Gronchi A, Fiore M, Dei Tos AP, Conca E, Palassini E, Vincenzi B, Grosso F, Pilotti S, Castelli C, Casali PG. **Efficacy and biological activity of imatinib in metastatic DFSP.** *Clin Cancer Res.* 2016; 22:837-46.
131. Fiore M, Colombo C, Radaelli R, Callegaro D, Palassini E, Barisella M, Morosi C, Baldi GG, **Stacchiotti S**, Casali PG, Gronchi A. **Hormonal manipulation with toramifene in sporadic desmoid-type fibromatosis.** *Eur J Cancer*, 2015; 51:2800-7.
132. Wardelmann E, Haas RL, Bovée JVMG, Terrier Ph, Lazar A, Messiou C, LePechoux C, Hartmann W, Collin F, Fisher C, Mechttersheimer G, Dei Tos AP, Stacchiotti S, Jones R, Gronchi A, Bonvalot S. **Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) recommendations for pathological examination and reporting.** *Eur J Cancer* 2015, 53:84-95.
133. Hindi N, Casali PG, Morosi C, Messina A, Palassini E, Pilotti S, Tamborini E, Radaelli S, Gronchi A, **Stacchiotti S.** **Imatinib in advanced chordoma: a retrospective case series analysis.** *Eur J Cancer*, 51:2609-14.
134. Dagrada GP, Negri T, Spagnuolo RD, Mauro V, Tamborini E, **Stacchiotti S**, Pierotti MA, Pilotti S. **Solitary fibrous tumor: loss of chimeric protein expression and genomic instability mark differentiation.** *Mod Pathol* 2015, 28:1074-83.
135. **Stacchiotti S** and Sommer J, on behalf of a Chordoma global consensus group. **Building a global consensus approach to chordoma: a position paper from the medical and patient community.** *Lancet Oncol* 2015, 16:71-83.
136. Provenzano S, Hindi N, Morosi C, Ghilardi M, Collini P, Casali PG, **Stacchiotti S.** **Response of conventional chondrosarcoma to gemcitabine alone: a case report.** *Clin Sarc Res* 2015;5:9.
137. Tazzari M, Palassini E, Vergani B, Villa A, Rini F, Negri T, Colombo C, Crippa F, Morosi C, Casali PG, Pilotti S, **Stacchiotti S**, Rivoltini L, Castelli C. **Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report.** *BMC Cancer*, 2015;15:1044.
138. Colombo C, Miceli M, Le Péchoux C, Palassini E, Honoré C, **Stacchiotti S**, Mir O , Casali PG, Dômont J, Fiore M, Le Cesne A, Gronchi A, Bonvalot S. **Sporadic Extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients.** *Eur J Cancer*, 2015 ; 51:186-92.
139. Morosi C, **Stacchiotti S**, Marchianò A, Bianchi A, Radaelli S, Sanfilippo R, Colombo C, Richardson C, Collini P, Barisella M, Casali PG, Gronchi A, Fiore M. **Correlation between radiological assessment and histopathological diagnosis in retroperitoneal tumors: analysis of 291 consecutive patients at a tertiary reference sarcoma center.** *Eur J Surg Oncol*, 2014; 40:1662-70.
140. Gronchi A, Collini P, Miceli R, Valeri B, Renne SL, Dagrada G, Fiore M, Sanfilippo R, Barisella M, Colombo C, Morosi C, **Stacchiotti S**, Casali PG, Dei Tos AP, Pilotti S. **Myogenic differentiation and histologic grading are major prognostic determinants in retroperitoneal liposarcoma.** *Am J Surg Path* 2015 ;39:383-93.

141. Palmerini E, Staals ES, Maki RG, Pengo S, Cioffi A, Gambarotti M, Picci P, Daolio PA, Parafioriti A, Morris C, Antonescu C, Gronchi A, Casali PG, Donati DM, Ferrari S, **Stacchiotti S. Tenosynovial giant cell tumour/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors.** Eur J Cancer, 2015; 51:210-7.
142. ESMO/European Sarcoma Network Working Group. **Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.** Ann Oncol. 2014 Sep;25 Suppl 3:iii113-23.
143. ESMO/European Sarcoma Network Working Group. **Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.** Ann Oncol. 2014 Sep;25 Suppl 3:iii21-6.
144. ESMO/European Sarcoma Network Working Group. **Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.** Ann Oncol. 2014 Sep;25 Suppl 3:iii102-12.
145. **Stacchiotti S**, Tortoreto M, Baldi GG, Grignani G, Toss A, Badalamenti G, Cominetti D, Morosi C, Dei Tos AP, Festinese F, Fumagalli E, Provenzano S, Gronchi A, Pennacchioli E, Negri T, Dagrada GP, Spagnuolo R, Pilotti S, Casali PG, Zaffaroni N. **Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumor.** Eur J Cancer 2014; 50:3021-8.
146. Gronchi A, Miceli R, Allard MA, Callegaro D, Le P echoux C, Fiore M, Honor e C, Sanfilippo R, Coppola S, **Stacchiotti S**, Terrier P, Casali PG, Le Cesne A, Mariani L, Colombo C, Bonvalot S. **Personalizing the approach to Retroperitoneal Soft Tissue Sarcoma: histology specific patterns of failure and post-relapse outcome after primary extended resection.** Ann Surg Oncol, 22:1447-54.
147. Tazzari M, Negri T, Rini F, Vergani B, Villa A, Dagrada GP, Colombo C, Gronchi A, **Stacchiotti S**, Casali PG, Pilotti S, Rivoltini L, Castelli C. **Anti-angiogenic therapy relieves local and systemic immune suppression in solitary fibrous tumour patients and favours the setting of adaptive immunity at the tumour site.** British J Cancer, 2014; 111:1350-62.
148. **Stacchiotti S**, Pantaleo MA, Astolfi A, Dagrada GP, Negri T, Dei Tos AP, Indio V, Morosi C, Gronchi A, Colombo C, Conca E, Toffolatti L, Tazzari M, Crippa F, Maestro R, Pilotti S, Casali PG. **Activity of sunitinib in extraskeletal myxoid chondrosarcoma.** Eur J Cancer 2014; 50:1657-64.
149. Radaelli S, **Stacchiotti S**, Casali PG, Gronchi A. **Emerging therapies for adult soft tissue sarcoma.** Expert Review of Anticancer Therapy, 2014; 14:689-704.
150. Bozzi F, Manenti G, Conca E, **Stacchiotti S**, Messina A, Dagrada G, Gronchi A, Panizza P, Pierotti M, Pilotti S, Tamborini E. **Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies.** Neuro Oncol. 2014; 16:72-80.
151. **Stacchiotti S**, Dagrada G, Sanfilippo R, Negri T, Vittimberga I, Ferrari S, Grosso F, Apice G, Tricomi M, Colombo C, Gronchi A, Dei Tos AP, Pilotti S and Casali PG. **Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study.** Clinical Sarcoma Research, 2013; 3:16.
152. Gronchi A, De Paoli A, Dani C, Merlo DF, Quagliuolo V, Grignani G, Bertola G, Navarra P, Sangalli C, Buonadonna A, De Sanctis R, Sanfilippo R, Dei Tos AP, **Stacchiotti S**, Giorello L, Fiore M, Bruzzi P, Casali PG. **Preoperative chemo-radiation therapy for localized retroperitoneal sarcoma: A phase I-II study from the Italian Sarcoma Group.** Eur J Cancer 2014; 50:784-92.
153. Martin-Broto J, Gutierrez AM, Ramos RF, Lopez-Guerrero JA, Ferrari S, **Stacchiotti S**, Picci P, Calabuig S, Collini P, Gambarotti M, Bague S, Dei Tos AP, Palassini E, Luna P, Cruz J, Cubedo R, Martinez-Trufero J, Poveda A, Casali PG, Fernandez A, Lopez-Pousa A, Gronchi A. **MRP1 overexpression determines poor prognosis in prospectively treated localized high risk soft tissue sarcoma patients of limbs and trunk wall. An ISG/GEIS study.** Mol Cancer Ther 2014; 13:249-59.
154. **Stacchiotti S**, Marrari A, Dei Tos AP, Casali PG. **Targeted therapies in rare sarcomas: IMT, ASPS, SFT, PEComa, and CCS.** Hematology/Oncology Clinics of North America 2013; 27:1049-61.
155. Castelli C, Tazzari M, Negri N, Vergani B, Rivoltini L, **Stacchiotti S**, Pilotti S. **Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcoma.** Journal of Translational Medicine, 2013; 11:237.
156. **Stacchiotti S**, Tortoreto M, Bozzi F, Morosi C, Messina A, Libertini M, Palassini E, Cominetti D, Negri T, Gronchi A, Pilotti S, Zaffaroni N, Casali PG. **Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis- a-vis temozolomide and antiangiogenics.** Clinical Cancer Research 2013, 19:5192-201.
157. **Stacchiotti S**, Crippa F, Messina A, Pilotti S, Gronchi A, Blay JY, Casali PG. **Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib.** Clinical Sarcoma Research, 2013; 3:8.
158. Duranti L, Gronchi A, **Stacchiotti S**, Fiore M, Casali PG, Collini P, Pelosi G, Galeone C, Pastorino U. **Localized thoracic sarcomas: outcome improvement over time at a single institution.** European Journal of Cancer, 2013; 49:2689-97.

159. Baldi GG, **Stacchiotti S**, Mauro V, Dei Tos AP, Gronchi A, Pastorino U, Duranti L, Provenzano S, Marrari A, Libertini M, Pilotti S, Casali PG. **Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients**. *Clinical Sarcoma Research* 2013; 3:4.
160. **Stacchiotti S**, Libertini M, Negri T, Palassini E, Gronchi A, Fatigoni S, Poletti PL, Vincenzi B, Dei Tos AP, Mariani L, Pilotti S, Casali PG. **Response to chemotherapy of solitary fibrous tumor: a retrospective study**. *European Journal of Cancer*, 2013; 49:2376-83.
161. Mattavelli D, Miceli R, Radaelli S, Mattavelli F, Cantù G, Barisella M, Quattrone P, **Stacchiotti S**, Sangalli S, Casali PG, Gronchi A, and Fiore M. **Head and neck soft tissue sarcomas: prognostic factors and outcome in a series of patients treated at a single institution**. *Ann Oncology* 2013, 24:2181-9.
162. **Stacchiotti S**, Tamborini, Lo Vullo S, Bozzi F, Messina A, Morosi C, Casale A, Crippa F, Conca E, Negri T, Palassini E, Marrari A, Palmerini E, Mariani L, Gronchi A, Pilotti S, Casali PG. **Phase 2 study on lapatinib in advanced EGFR-positive chordoma**. *Ann Oncology* 2013, 24:1931-6.
163. ESMO / European Sarcoma Network Working Group **Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up**. *Ann Oncol*. 2012 Oct;23 Suppl 7:vii92-9
164. ESMO / European Sarcoma Network Working Group. **Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up**. *Ann Oncol*. 2012 Oct;23 Suppl 7:vii49-55.
165. ESMO / European Sarcoma Network Working Group. **Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up**. *Ann Oncol*. 2012 Oct;23 Suppl 7:vii100-9.
166. **Stacchiotti S**, Dagrada G, Morosi C, Negri T, Romanini A, Pilotti S, Gronchi A, Casali PG. **Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib**. *Clinical Sarcoma Research* 2012; 2:22.
167. Gronchi A, Verderio P, De Paoli A, Ferraro A, Tendero O, Majò J, Martin J, Comandone A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, Palassini E, **Stacchiotti S**, Ferrari S, Fiore M, Casali PG. **Quality of surgery and neoadjuvant combined therapy in the ISG_GEIS trial of soft tissue sarcomas of limbs and trunk wall**. *Ann Oncol* 2012, 24:817-23.
168. **Stacchiotti S**, Negri T, Libertini M, Palassini E, Marrari A, De Troia B, Gronchi A, Dei Tos P, Morosi C, Messina A, Pilotti S, Casali PG. **Sunitinib in solitary fibrous tumor**. *Ann Oncol* 2012; 23:3171-9.
169. **Stacchiotti S**, Verderio P, Messina A, Morosi C, Collini P, Lombart Bosch A, Martin J, Comandone A, Cruz J, Ferraro A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, Casali P, Gronchi A. **Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy: an exploratory analysis on a Phase III trial**. *Cancer* 2012, 118:5857-66.
170. Collini P, Negri T, Barisella M, **Stacchiotti S**, Palassini E, Pastorino U, Gronchi A, Casali PG, Pilotti S. **High-grade sarcomatous overgrowth in solitary fibrous tumor: a clinico-pathological study of 10 cases**. *Am J Surg Path* 2012, 36:1202-1215.
171. Colombo C, Miceli R, Collini P, Radaelli S, Palassini E, **Stacchiotti S**, Fiore M, Mariani L, Casali P, Gronchi A. **Leiomyosarcoma and sarcoma with myogenic differentiation: two different entities or two faces of the same disease?** *Cancer*, 118: 5349-57.
172. **Stacchiotti S**, Longhi A, Ferraresi V, Grignani G, Comandone A, Stupp R, Bertuzzi A, Tamborini E, Pilotti S, Messina A, Spreafico C, Gronchi A, Amore P, Vinaccia V, Casali PG. **A phase II study on imatinib in advanced chordoma**. *JCO* 2012; 30:914-20
173. Gronchi A, Frustaci S, Mercuri M, Martin J, Lopez Pousa A, Verderio P, Mariani L, Valagussa P, Miceli R, **Stacchiotti S**, Dei Tos AP, De Paoli A, Longhi A, Poveda AM, Quagliuolo V, Comandone A, Casali PG, Picci P. **Short, Full-Dose Adjuvant Chemotherapy In High-Risk Adult Soft Tissue Sarcomas (STS): A Randomized Clinical Trial From The Italian Sarcoma Group (ISG) And The Spanish Sarcoma Group (GEIS)**. *JCO* 2012; 30:850-6.
174. Gronchi A, Miceli M, Colombo C, **Stacchiotti S**, Collini P, Mariani L, Sangalli C, Radaelli S, Sanfilippo R, Fiore M, Casali PG. **Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas**. *Ann Oncol*; 23:1067-73.
175. Cassier PA, Gelderblom H, **Stacchiotti S**, Thomas D, Maki RG, Kroep JR, T van der Graaf W, Italiano A, Seddon B, Dömöt J, Bompas E, Wagner AJ, Blay JY **Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis**. *Cancer* 2012; 118:1649-55.
176. Negri T, Bric S, Conca E, Bozzi F, Orsenigo M, **Stacchiotti S**, Alberghini M, Mauro V, Gronchi A, Dusio GF, Pelosi G, Picci P, Casali PG, Pierotti MA, Pilotti S. **Receptor Tyrosine Kinase Pathway Analysis Sheds Light on Similarities between Clear Cell Sarcoma and Metastatic Melanoma**. *Genes, Chromosomes and Cancer*, 2012; 51:111-26

177. **Stacchiotti S**, Palassini E, Sanfilippo R, Vincenzi B, Arena MG, Bochicchio AM, De Rosa P, Nuzzo A, Turano S, Morosi C, Dei Tos AP, Pilotti S, Casali PG. **Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network.** *Ann Oncol* 2012; 23: 501-8.
178. **Stacchiotti S**, Casali PG. **Systemic therapy options for unresectable and metastatic chordomas.** *Curr Oncol Rep* 2011; 13: 323-30.
179. Gronchi A, Miceli R, Colombo C, Collini P, **Stacchiotti S**, Olmi P, Mariani L, Bertulli R, Fiore M, Casali PG. **Primary extremity soft tissue sarcomas: outcome improvement over time at a single institution.** *Ann Oncol.* 2011, 22:1675-81.
180. **Stacchiotti S**, Negri T, Zaffaroni T, Palassini E, Morosi C, Brich S, Conca E, Bozzi F, Cassinelli G, Gronchi A, Casali PG and Pilotti S. **Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect.** *Ann Oncol* 2011; 22:1682-90.
181. **Stacchiotti S**, Pedeutour F, Conca E, Marrari A, Palassini E, Collini P, Keslair F, Morosi C, Gronchi A, Pilotti S and Casali PG. **Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib.** *Int J Cancer*, 2011; 129:1761-72.
182. Grignani G, Palmerini E, **Stacchiotti S**, Boglione A, Ferraresi V, Frustaci S, Comandone A, Aliberti S, Casali PG, Ferrari S, Aglietta M. **A phase II trial of imatinib mesylate in relapsed non-resectable chondrosarcomas expressing platelet derived growth factor receptor-alpha or -beta: an Italian Sarcoma Group study.** *Cancer* 2011; 117:826-31.
183. Dileo P, Pricl S, Tamborini E, Negri T, **Stacchiotti S**, Gronchi A, Posocco P, Laurini E, Coco P, Fumagalli E, Casali PG, Pilotti S. **Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: An imaging, biochemical and molecular modeling study.** *Int J Cancer* 2011; 128:983-90.
184. Pennacchioli E, Fiore M, Collini P, Radaelli S, Dileo P, **Stacchiotti S**, Casali PG, Gronchi A. **Alveolar Soft Part Sarcoma: Clinical Presentation, Treatment, and Outcome in a Series of 33 Patients at a Single Institution.** *Ann Surg Oncol.* 2010; 17:3229-33.
185. **Stacchiotti S**, Negri T, Palassini E, Conca E, Gronchi A, Morosi C, Messina A, Pastorino U, Pierotti MA, Casali PG, Pilotti S. **Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response.** *Mol Cancer Ther.* 2010; 9:1286-97.
186. Ardoino I, Miceli R, Berselli M, Mariani L, Biganzoli E, Fiore M, Collini P, **Stacchiotti S**, Casali PG, Gronchi A. **Histology-specific nomogram for primary retroperitoneal soft tissue sarcoma.** *Cancer* 2010; 116: 2429-36.
187. **Stacchiotti S**, Grosso F, Negri T, Palassini E, Morosi C, Pilotti S, Gronchi A, Casali PG. **Tumor response to sunitinib malate observed in clear cell sarcoma.** *Ann Oncol* 2010; 21:1130-1.
188. Tamborini E, Viridis E, Negri T, Orsenigo M, Brich S, Conca E, Gronchi A, **Stacchiotti S**, Manenti G, Casali PG, Pierotti MA and Pilotti S. **Analysis of receptor tyrosine kinase and downstream pathways in chordomas.** *Neuro Oncology* 2010; 12: 776-89.
189. Gronchi A, Lo Vullo S, Colombo C, Collini P, **Stacchiotti S**, Mariani L, Fiore M, Casali Paolo. **Extremity soft tissue sarcoma in a series of patients treated at a single institution: the local control directly impacts survival** *Annals of Surgery.* *Ann Surgery* 2010; 251, 512-517.
190. **Stacchiotti S**, Casali PG, Salvatore Lo Vullo, Luigi Mariani, Elena Palassini, Mario Mercuri, Marco Alberghini, Silvana Pilotti, Lucciana Zanella, Alessandro Gronchi, and Piero Picci. **Chordoma of the Mobile Spine and Sacrum: A Retrospective Analysis of a Series of Patients Surgically Treated at Two Referral Centers.** *Ann Surg Oncol* 2010; 17, 211-219.
191. **Stacchiotti S**, Marrari A, Tamborini E, Palassini E, Viridis E, Messina A, Crippa F, Morosi C, Gronchi A, Pilotti S and Casali PG. **Response to imatinib plus sirolimus in advanced chordoma.** *Ann Oncol* 2009; 20:1886-94.
192. **Stacchiotti S**, Collini P, Messina A, Morosi A, Bertulli R, Dileo P, Piovesan C, Gronchi A, Casali PG. **Tumor response assessment in high-grade soft tissue sarcomas (STS): a pilot study to assess the correlation between radiological and pathological response using both RECIST and Choi's criteria.** *Radiology*, 2009; 251:447-56.
193. Fiore M, Palassini E, Fumagalli E, Pilotti S, Tamborini E, **Stacchiotti S**, Pennacchioli E, Casali PG, Gronchi A. **Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).** *Eur J Surg Oncol*, 2009; 35:739-45
194. **Stacchiotti S**, Tamborini E, Marrari A, Brich S, Rota SA, Orsenigo M, Crippa F, Morosi C, Gronchi A, Pierotti MA, Casali PG, Pilotti S. **Response to Sunitinib Malate in Advanced Alveolar Soft Part Sarcoma (ASPS).** *Clin Cancer Res*, 2009; 15:1096-104.

195. Gronchi A, Lo Vullo S, Fiore M, Mussi C, Stacchiotti S, Collini P, Lozza L, Pennacchioli E, Mariani L, Casali PG. **Aggressive Surgical Policies in a Retrospectively Reviewed Single-Institution Case Series of Retroperitoneal Soft Tissue Sarcoma Patients**. J Clin Oncol, 2009; 27: 24-30.
196. Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, Sanfilippo R, Casieri P, Collini P, Dileo P, Spreafico C, **Stacchiotti S**, Tamborini E, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Fletcher JA, Pilotti S, Casali PG. **Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study**. Lancet Oncol, 2007; 8:595-602.
197. Casali PG, **Stacchiotti S**, Sangalli C, Olmi P, Gronchi A. **Chordoma**. Curr Opin Oncol, 2007; 19: 367-70.
198. Fiore M, Grosso F, Lo Vullo S, Pennacchioli E, **Stacchiotti S**, Ferrari A, Collini P, Lozza L, Mariani L, Casali PG, Gronchi A. **Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution**. Cancer, 2007; 109: 2522-31.
199. Tamborini E, Casieri P, Piselli F, Orsenigo M, Negri T, Piacenza C, **Stacchiotti S**, Gronchi A, Pastorino U, Pierotti MA, Pilotti S. **Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas**. J Pathol, 2007; 212: 227-235.
200. Negri T, Casieri P, Piselli F, Orsenigo M, Piacenza C, **Stacchiotti S**, Bidoli P, Casali PG, Pienotti MA, Tamborini E, Pilotti S. **Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient**. Br J Cancer, 2007; 96: 180-181.
201. Manoukian S, Peissel B, Pensotti V, Barile M, Cortesi L, **Stacchiotti S**, Terenziani M, Barbera F, Pasquini G, Frigerio S, Pienotti MA, Radice P, Della Torre G. **Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families**. Eur J Cancer, 2007; 43: 601-606.
202. Ferrari A, Grosso F, **Stacchiotti S**, Meazza C, Zaffignani E, Marchianò A, Casanova M. **Response to Vinorelbine and low dose Cyclophosphamide chemotherapy in two patients with desmoplastic small round cell tumor**. Pediatr Blood Cancer, 2007; 49(6):864-6.
203. Tamborini E, Miselli F, Negri T, Lagonigro MS, Staurengo S, Dagrada GP, **Stacchiotti S**, Pastore E, Gronchi A, Perrone F, Carbone A, Pierotti MA, Casali PG, Pilotti S. **Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas**. Clin Cancer Res, 2006; 12: 6920-8.
204. Grosso F, Dileo P, Sanfilippo R, **Stacchiotti S**, Bertulli R, Piovesan C, Jimeno J, D'Incalci M, Gescher A, Casali PG. **Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma**. Eur J Cancer, 2006; 42: 1484-90.
205. Casali PG, Bertulli R, Fumagalli E, Coco P, Grosso F, **Stacchiotti S**. **Some lessons learned from imatinib mesylate clinical development in gastrointestinal stromal tumors**. J Chemother, 2004;16 Suppl 4: 55-58.
206. Casali PG, Messina A, **Stacchiotti S**, Tamborini E, Crippa F, Gronchi A, Orlandi R, Ripamonti C, Spreafico C, Bertieri R, Bertulli R, Colecchia M, Fumagalli E, Greco A, Grosso F, Olmi P, Pierotti MA, Pilotti S. **Imatinib mesylate in chordoma**. Cancer, 2004; 101: 2086-2097.
207. Gavazzi C, **Stacchiotti S**, Cavalletti R, Lodi R. **Confusion after antibiotics**. Lancet, 2001; 357: 1410.

“Acconsento al trattamento dei dati personali ai sensi del Regolamento (UE) 2016/679 e autorizzo all’utilizzo del suddetto Curriculum Vitae ai fini della procedura per la quale è presentato”